•There is an association between clinical outcomes and development of cutaneous toxicities due to anticancer therapeutics.•Vitiligo, rash, nail toxicity, or alopecia induced by anticancer therapeutics may be potential biomarkers in predicting treatment efficacy.•Identification of cutaneous toxicities may be an early and non-invasive way to determine cancer treatment efficacy.
Παρασκευή 4 Μαΐου 2018
Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasisBackground: Psoriasis (PSO) is an autoimmune disease causing patches of thick, inflamed, scaly skin due to excessive proliferation of skin c...
-
Clinical and animal studies show that ethanol exposure and inflammation during pregnancy cause similar behavioral disturbances in the offspr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.